From bad to worse: the shortage of fibrinolytics

Lorenz Roger Van der Linden,Jens Neefs,Thomas Vanassche,Robin Lemmens,Peter Verhamme
DOI: https://doi.org/10.1136/ejhpharm-2023-003719
2023-04-22
European Journal of Hospital Pharmacy: Science and Practice
Abstract:The problem of ongoing drug shortages is increasing pressure on pharmacists, prescribers and patients. Unfortunately, this situation is nothing new. Hospital pharmacists are commonly at the forefront of this battle, investing increasing amounts of time to identify, follow-up and resolve these shortages.1 2 While drug shortages might initially have been perceived as merely a logistical nuisance, this has now changed substantially, since patients are increasingly at risk for harm due to therapeutic agents simply not being available. One specific shortage currently affecting healthcare systems worldwide concerns fibrinolytics, used in an array of indications. According to current estimates, global availability will not be restored until well into 2024. Reasons for unavailability include a limited number of manufacturers, (vulnerable) single-site production facilities, high(er) quality standards (along with concomitant quality issues), and last but not least an increased use of the involved drug (class).3 4 Driving factors underlying these causes are frequently economic in nature. Given the clinical impact of this specific shortage, a task force has been assembled by the Belgian Federal Agency for Medicines and Health Products (FAMHP). In Belgium, a clinically relevant issue has arisen with alteplase, a fibrinolytic agent primarily used to treat ischaemic stroke and haemodynamically unstable pulmonary embolism (unstable PE).5 6 The manufacturer relies on these two indications to determine its annual forecast. The authors of this Editorial are all active in the University Hospitals Leuven, a large, academic hospital situated in a highly urbanised region (Leuven, Belgium). Rather poignantly, our alma mater KU Leuven played a major role in the ... Correspondence to Professor Lorenz Roger Van der Linden, Hospital Pharmacy Department, UZ Leuven, Leuven 49, Flanders, Belgium; lorenz.vanderlinden{at}uzleuven.be
What problem does this paper attempt to address?